Qiagen, AstraZeneca collaborate on companion diagnostics

Nearly a decade after their successful collaboration in cancer treatment, AstraZeneca and Qiagen are set to combine their technologies once more, this time directing their efforts toward complex chronic diseases. The initial partnership saw success in 2015 when the FDA approved AstraZeneca's non–small-cell lung cancer (NSCLC) drug, Iressa (gefitinib), for use in patients with EGFR mutations identified through Qiagen's therascreen companion diagnostic test. This collaboration initially began in 2014, with an agreement to co-develop and market a liquid biopsy for Iressa, a drug that received its first clearance from the US regulator in 2003, but was later pulled from the market. 

In their latest partnership, announced this Wednesday, AstraZeneca and Qiagen aim to address complex chronic diseases. Qiagen will lead the development and validation of a genotyping assay using its QIAstat-Dx syndromic testing platform. The goal is to have this diagnostic test available during routine clinical visits, enabling healthcare providers to make rapid decisions about whether a patient could benefit from one of AstraZeneca's precision medicines, which may be either approved or in investigational stages. 

Qiagen's molecular diagnostics capabilities are pivotal to this collaboration. The company’s tests are designed to be user-friendly, employing single-use cartridges that incorporate sample processing and on-board reagents, delivering results in approximately an hour. This rapid turnaround is particularly beneficial in clinical settings, where timely decision-making can significantly impact patient outcomes.

The renewed collaboration emphasizes the importance of genomically targeted precision medicines. These treatments are tailored based on the genetic makeup of the patient, aiming to provide more effective and personalized therapeutic options. By combining AstraZeneca's expertise in precision medicines with Qiagen's advanced diagnostic technologies, the partnership seeks to bring innovative solutions to the management of chronic diseases, potentially transforming patient care.

This strategic alliance highlights the ongoing evolution in the field of precision medicine. By extending their collaboration beyond oncology and into chronic disease management, AstraZeneca and Qiagen are paving the way for the development of new diagnostic tools and treatments that could offer significant benefits to patients. The integration of advanced diagnostics with targeted therapies represents a forward-thinking approach to healthcare, promising more precise and effective treatment options for complex chronic conditions.

In summary, the latest collaboration between AstraZeneca and Qiagen marks a significant step towards advancing the management of chronic diseases through precision medicine. By leveraging Qiagen's diagnostic technology and AstraZeneca's expertise in targeted therapies, the partnership aims to enhance clinical decision-making and improve patient outcomes. The development of a rapid genotyping assay for use during routine clinical visits could enable timely and personalized treatment interventions, illustrating the potential of genomically targeted precision medicines in addressing complex health challenges.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!